UPC_CFI_80/2023

Order following the interim conference (R. 105.5 RoP) in the revocation action by Astellas Institute for Regenerative Medicine against Healios K.K. and Osaka University (EP 3 056 564) at the Munich Section of the Central Division. The court confirmed the oral hearing would proceed as planned and admitted a second expert declaration (D21) conditionally, giving the defendant limited time to reply.

The Munich Central Division refused a request by Healios K.K. and Osaka University to stay UPC revocation proceedings pending a decision by the EPO, finding no concrete near-future date for an EPO decision and holding that the interests of the parties must be weighed, with the claimant's interest in timely proceedings prevailing.

The Munich Central Division issued an order on a Rule 262A application by Astellas Institute for Regenerative Medicine to restrict access to a confidential annex, addressing the scope of access permitted to named individuals at the defendant entities Healios K.K. and Osaka University in the revocation action concerning EP 3 056 564.

The Munich Central Division issued a Rule 9 RoP procedural order directing parties to use the CMS and designated workflows for all submissions and limiting external correspondence to a minimum, in the revocation action by Astellas against Healios K.K. and Osaka University.